Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients (PROTEOHSEPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00930085|
Recruitment Status : Completed
First Posted : June 30, 2009
Last Update Posted : September 14, 2011
|Condition or disease||Intervention/treatment||Phase|
|Sepsis Septic Shock Cancer||Other: SELDI-TOF MS for plasmatic proteic profile||Not Applicable|
Method: Monocentric prospective study with diagnostic and prognostic expectations.
Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock.
Research of clinical and biological prognostic factors.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||May 2011|
Experimental: SELDI-TOF MS
The proteic profiling is performed by SELDI-TOF mass spectroscopy.
Other: SELDI-TOF MS for plasmatic proteic profile
An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
- Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock. [ Time Frame: 1 month ]
- Research of clinical and biological prognostic factors. [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00930085
|Principal Investigator:||Djamel MOKART, MD||Institut Paoli-Calmettes|